ponatinib
incyte,takeda,otsuka
['ponatinib']
 the efficacy and safety results demonstrate a favorable benefit/risk assessment for ponatinib and should be considered a soc for frontline therapy in patients with newly diagnosed ph-positive all, said elias jabbour, md. #all | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.